メニュー

血管生理学部

スタッフ
中岡 良和

スタッフ紹介 [中岡 良和]

氏名中岡 良和中岡 良和 写真
よみなかおか よしかず
所属・職務血管生理学部・部長
内線番号31013
FAX番号06-6170-1695
Eメールynakaoka@ncvc.go.jp
棟/部屋番号研究所(C棟)5階
専門循環器内科学、血管生物学、炎症性血管病(高安動脈炎、肺高血圧症など)
循環器疾患と腸内細菌叢
主要論文・著書
  • Ishibashi T, Inagaki K, Okazawa M, Yamagishi A, Ohta-Ogo K, Asano R, Masaki T, Kotani Y, Ding X, Chikaishi-Kirino T, Maedera N, Shirai M, Hatakeyama K, Kubota Y, Kishimoto T, Nakaoka Y. IL-6/gp130 signaling in CD4+ T cells drives the pathogenesis of pulmonary hypertension. Proc Natl Acad Sci U S A. 2024 Apr 16;121(16):e2315123121. doi: 10.1073/pnas.2315123121. Epub 2024 Apr 11.
  • Manabe Y, Ishibashi T, Asano R, Tonomura S, Maeda Y, Motooka D, Ueda J, Yanagawa M, Edamoto-Taira Y, Chikaishi-Kirino T, Masaki T, Inagaki T, Nakamura S, Katada Y, Okazawa M, Narazaki M, Ogo T, Kumanogoh A, Nakaoka Y*. Gut Dysbiosis is associated with aortic aneurysm formation and progression in Takayasu arteritis. Arthritis Res Ther. 2023 March 24; 25(1); 46. doi:1186/s13075-023-03031-9.
  • Yaku A, Inagaki T, Asano R, Okazawa M, Mori H, Sato A, Hia F, Masaki T, Manabe Y, Ishibashi T, Vandenbon A, Nakatsuka Y, Akaki K, Yoshinaga M, Uehata T, Mino T, Ishibashi-Ueda H, Morinobu A, Tsujimura T, Ogo T, Nakaoka Y*, Takeuchi O*. Regnase-1 prevents pulmonary arterial hypertension via mRNA degradation of Interleukin-6 and Platelet-Derived Growth Factor in alveolar macrophages. Circulation. 2022 Sep 27;146(13):1006-1022 (*equal contribution, *co-correspondence)
  • Harigai M, Miyamae T, Hashimoto H, Yoshida A, Yamashita K, Nakaoka Y. A Multicentre, Large-Scale, Observational Study of Tocilizumab in Patients with Takayasu Arteritis in Japan: The ACT-Bridge Study. Mod Rheumatol. 2022 Sep 3; roac099. doi:10.1093/mr/roac099. Online ahead of print.
  • Nakaoka Y*, Yanagawa M, Hata A, Yamashita K, Okada N, Yamakido S, Hayashi H, Jayne D. Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial. Rheumatology (Oxford). 2022 May 30; 61(6):2360-2368. doi: 10.1093/rheumatology/keab684.
  • Masaki T, Okazawa M, Asano R, Inagaki T, Ishibashi T, Yamagishi A, Mizushima S, Nishimura M, Manabe Y, Ishibashi-Ueda H, Shirai M, Tsuchimochi H, Pearson JT, Kumanogoh A, Sakata Y, Ogo T, Kishimoto T, Nakaoka Y*. Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 118(11): e2023899118, 2021
  • Inagaki T, Pearson JT, Tsuchimochi H, Schwenke DO, Saito S, Higuchi T, Masaki T, Umetani K, Shirai M, Nakaoka Y. * Evaluation of right coronary vascular dysfunction in severe pulmonary hypertensive rats using synchrotron radiation microangiography. Am J Physiol Heart Circ Physiol. 2021 Mar 1; 320(3):H1021-H1036. doi:10.1152/ajpheart.00327.2020. Epub 2021 Jan 22.
  • Arita Y, Nakaoka Y, Eda Y, Kitabayashi K, Hasegawa S. Perioperative Management of Takayasu Arteritis for Cardiac Surgery in a Patient Treated With Tocilizumab. J Am Coll Cardiol Case Rep. 2020 Oct 7; 2(15); 2363–2367.doi: 10.1016/j.jaccas.2020.07.039. eCollection 2020 Dec.
  • Nakaoka Y*, Yamashita K, Yamakido S. Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply. Rheumatology (Oxford). 2020 Sep 1;59(9):e48-e49. doi: 10.1093/rheumatology/keaa255.
  • Mori H, Ishibashi T, Inagaki T, Okazawa M, Masaki T, Asano R, Manabe Y, Ohta-Ogo K, Narazaki M, Ishibashi-Ueda H, Kumanogoh A,Nakaoka Y*. Pristane/Hypoxia (PriHx) Mouse as a Novel Model of Pulmonary Hypertension Reflecting Inflammation and Fibrosis. Circ J. 2020 Jun 25;84(7):1163-1172.
  • Minato T, Nirasawa S, Sato T, Yamaguchi T, Hoshizaki M, Inagaki T, Nakahara K, Yoshihashi T, Ozawa R, Yokota S, Natsui M, Koyota S, Yoshiya T, Yoshizawa-Kumagaye K, Motoyama S, Gotoh T, Nakaoka Y, Penninger JM, Watanabe H, Imai Y, Takahashi S, Kuba K. B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction. Nat Commun. 2020 Feb 26;11(1):1058. doi: 10.1038/s41467-020-14867-z
  • Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, Kobayashi S, Komagata Y, Komuro I, Komori K, Takahashi K, Tanemoto K, Hasegawa H, Harigai M, Fujimoto S, Miyazaki T, Miyata T, Yamada H, Yoshida A, Wada T, Inoue Y, Uchida HA, Ota H, Okazaki T, Onimaru M, Kawakami T, Kinouchi R, Kurata A, Kosuge H, Sada KE, Shigematsu K, Suematsu E, Sueyoshi E, Sugihara T, Sugiyama H, Takeno M, Tamura N, Tsutsumino M, Dobashi H, Nakaoka Y, Nagasaka K, Maejima Y, Yoshifuji H, Watanabe Y, Ozaki S, Kimura T, Shigematsu H, Yamauchi-Takihara K, Murohara T, Momomura SI; JCS Joint Working Group. JCS 2017 Guideline on Management of Vasculitis Syndrome - Digest Version. Circ J. 2020 Jan 24;84(2):299-359. doi: 10.1253/circj.CJ-19-0773.
  • Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, Tamura N, Banno S, Yoshifuji H, Sakata Y, Kawakami A, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, Okada N, Yamakido S, Takei S, Yokota S, and Nishimoto N. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomised controlled phase 3 TAKT study. Rheumatology (Oxford). 2020 Jan 17. pii: kez630. doi: 10.1093/rheumatology/kez630. [Epub ahead of print]PMID:31951279
  • Terao C, Yoshifuji H, Matsumura T, Naruse TK, Ishii T, Nakaoka Y, Kirino Y, Matsuo K, Origuchi T, Shimizu M, Maejima Y, Amiya E, Tamura N, Kawaguchi T, Takahashi M, Setoh K, Ohmura K, Watanabe R, Horita T, Atsumi T, Matsukura M, Miyata T, Kochi Y, Suda T, Tanemoto K, Meguro A, Okada Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayamada S, Saito K, Kuwana M, Mizuki N, Tabara Y, Ueda A, Komuro I, Kimura A, Isobe M, Mimori T, Matsuda F. Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis. Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):13045-13050.
  • Kim KH, Nakaoka Y, Augustin HG, Koh GY. Myocardial Angiopoietin-1 Controls Atrial Chamber Morphogenesis by Spatiotemporal Degradation of Cardiac Jelly. Cell Reports, 23, 2455-2466, May 22, 2018
  • Nakaoka Y*, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomized, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018 Mar; 77(3):348-354. doi: 10.1136/annrheumdis-2017-211878. Epub 2017 Nov 30.
  • Yasui T, Masaki T, Arita Y, Ishibashi T, Inagaki T, Okazawa M, Oka T, Shioyama W, Yamauchi-Takihara K, Komuro I, Sakata Y, Nakaoka Y*. Molecular Characterization of Striated Muscle-specific Gab1 Isoform as a Critical Signal Transducer for Neuregulin-1/ErbB Signaling in Cardiomyocytes. PLoS One. 2016 Nov 18;11(11): e0166710. doi: 10.1371/journal.pone.0166710
  • Han S, Lee SJ, Kim KE, Lee HS, Oh N, Park I, Ko E, Oh SJ, Lee YS, Kim D, Lee S, Lee DH, Lee KH, Chae SY, Lee JH, Kim SJ, Kim HC, Kim S, Kim SH, Kim C, Nakaoka Y, He Y, Augustin HG, Hu J, Song PH, Kim YI, Kim P, Kim I, Koh GY. Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med. 2016 Apr 20;8(335):335ra55. doi: 10.1126/scitranslmed.aad9260.9.
  • Furuta K, Yoshida Y, Ogura S, Kurahashi T, Kizu T, Maeda S, Egawa M, Chatani N, Nishida K, Nakaoka Y, Kiso S, Kamada Y, Takehara T. Gab1 adaptor protein acts as a gatekeeper to balance hepatocyte death and proliferation during acetaminophen-induced liver injury in mice. Hepatology. 2016 Apr;63(4):1340-55. doi: 10.1002/hep.28410. Epub 2016 Jan 22.
  • Hashimoto-Kataoka T, Hosen N, Sonobe T, Arita Y, Yasui T, Masaki T, Minami M, Inagaki T, Miyagawa S, Sawa Y, Murakami M, Kumanogoh A, Yamauchi-Takihara K, Okumura M, Kishimoto T, Komuro I, Shirai M, Sakata Y, Nakaoka Y.* Interleukin-6/interleukin-21-signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2015 May 19; 112(20): E2677-86.
  • Arita Y, Nakaoka Y*, Matsunaga T, Kidoya H, Yamamizu K, Arima Y, Hashimoto-Kataoka T, Ikeoka K, Yasui T, Masaki T, Yamamoto K, Higuchi K, Park JS, Shirai M, Nishiyama K, Yamagishi H, Otsu K, Kurihara H, Minami T, Yamauchi-Takihara K, Koh GY, Mochizuki N, Takakura N, Sakata Y, Yamashita JK, Komuro I. Myocardium-derived angiopoietin-1 is essential for coronary vein formation in the developing heart. Nat Commun. 2014 Jul 29; 5: 4552. doi: 10.1038/ncomms5552.
  • Lee J, Kim KE, Choi DK, Jang JY, Jung JJ, Kiyonari H, Shioi G, Chang W, Suda T, Mochizuki N, Nakaoka Y, Komuro I, Yoo OJ, Koh GY. Angiopoietin-1 guides directional angiogenesis through integrin αvβ5 signaling for recovery of ischemic retinopathy. Sci Transl Med. 2013 Sep 18;5(203):203ra127. doi: 10.1126/scitranslmed.3006666.
  • Nakaoka Y*, Higuchi K, Arita Y, Otsuki M, Yamamoto K, Hashimoto-Kataoka T, Yasui T, Ikeoka K, Ohtani T, Sakata Y, Shima Y, Kumanogoh A, Yamauchi-Takihara K, Tanaka T, Kishimoto T, Komuro I. Tocilizumab for the Treatment of the Patients with Refractory Takayasu Arteritis. Int Heart J. 54, 406-411, 2013
  • Shioyama W, Nakaoka Y*, Higuchi K, Minami T, Nishida K, Taniyama Y, Kidoya H, Arita Y, Hashimoto T, Fujio Y, Shirai M, Takakura N, Morishita R, Yamauchi-Takihara K, Kodama T, Hirano T, Mochizuki N, Komuro I*. Gab1 is essential for postnatal angiogenesis via hepatocyte growth factor/c-Met signaling. Circ Res. 108, 664-675, 2011.
  • Koyama T, Nakaoka Y*, Fujio Y, Hirota H, Nishida K, Sugiyama S, Okamoto K, Yamauchi-Takihara K, Yoshimura M, Mochizuki S, Hori M, Hirano T, Mochizuki N. Interaction of Scaffolding Adaptor Protein Gab1 with Tyrosine Phosphatase SHP2 Negatively Regulates IGF-I-dependent Myogenic Differentiation via the ERK1/2 Signaling Pathway. J Biol Chem. 283: 24234-24244, 2008
  • Nakaoka Y*, Nishida K, Narimatsu M, Kamiya A, Minami T, Sawa H, Okawa K, Fujio Y, Koyama T, Maeda M, Sone M, Yamasaki S, Arai Y, Koh GY, Kodama T, Hirota H, Otsu K, Hirano T, and Mochizuki N*. Gab family proteins are essential for postnatal maintenance of cardiac function through transmitting neuregulin-1/ErbB signaling. J Clin Invest. 117: 1771-1781, 2007
  • Nakaoka Y, Nishida K, Fujio Y, Izumi M, Terai T, Oshima Y, Sugiyama S, Matsuda S, Koyasu S, Yamauchi-Takihara K, Hirano T, Kawase I, Hirota H. Activation of gp130 Transduces Hypertrophic Signal Through Interaction of Scaffolding Docking Protein Gab1 With Tyrosine Phosphatase SHP2 in Cardiomyocytes. Circ Res. 93: 221-229, 2003 

 (*corresponding author)

受賞日本心不全学会YIA最優秀賞(2006年10月)、
日本循環器学会 第17回八木賞(2007年3月)、
大阪大学総長奨励賞(2014年7月)
日本肺高血圧・肺循環学会 八巻賞(2022年7月)
学位博士(医学) 大阪大学
所属学会日本血管生物医学会(理事・評議員)、日本循環器学会(FJCS)、日本内科学会、日本肺循環学会・日本肺高血圧学会(理事・評議員)、日本心不全学会、ISHR日本部会(評議員)、国際心血管薬物療法学会(JCVA)(評議員)
教育活動大阪大学大学院医学系研究科循環器内科学・招聘教授
http://www.cardiology.med.osaka-u.ac.jp/?page_id=10
大阪大学大学院医学系研究科連携大学院循環微小画像医学・招聘教授
http://www.med.osaka-u.ac.jp/introduction/research/affiliate/molecular
その他の活動科学技術振興機構さきがけ 「生体における動的恒常性維持・変容機構の解明と制御」領域統括・春日雅人(国際医療センター理事長)
さきがけ研究者
http://www.jst.go.jp/presto/hody/researcher/0210nakaoka/index.html
厚生労働省難治性血管炎に関する調査研究班・大型血管炎臨床分科会長
http://www.vas-mhlw.org/index.html
Fellow of the ISHR (International Society of Heart Research)
https://ishrworld.org/page/Fellows
研究者情報J-GLOBAL ID:200901055486447874
researchmap: https://researchmap.jp/ynakaoka_1969
リンク大阪大学大学院医学系研究科循環器内科学 (URL)
http://www.cardiology.med.osaka-u.ac.jp/?page_id=66
大阪大学大学院医学系研究科連携大学院循環微小画像医学
http://www.med.osaka-u.ac.jp/introduction/research/affiliate/molecular

最終更新日:2024年05月27日

各部の紹介About

設定メニュー